参考文献/References:
[1] Roth GA,Mensah GA,Johnson CO,et al. Global burden of cardiovascular diseases and risk factors,1990-2019:update from the GBD 2019 study[J]. J Am Coll Cardiol,2020,76(25):2982-3021.
[2] Li SX,Patel NK,Flannery LD,et al. Trends in utilization of aortic valve replacement for severe aortic stenosis[J]. J Am Coll Cardiol,2022,79(9):864-877.
[3] Lee G,Chikwe J,Milojevic M,et al. ESC/EACTS vs. ACC/AHA guidelines for the management of severe aortic stenosis[J]. Eur Heart J,2023,44(10):796-812.
[4] Ahmad Y,Howard JP,Arnold AD,et al. Transcatheter versus surgical aortic valve replacement in lower-risk and higher-risk patients:a meta-analysis of randomized trials[J]. Eur Heart J ,2023,44(10):836-852.
[5] J?rgensen TH,Thyregod HGH,Ihlemann N,et al. Eight-year outcomes for patients with aortic valve stenosis at low surgical risk randomized to transcatheter vs. surgical aortic valve replacement[J]. Eur Heart J ,2021,42(30):2912-2919.
[6] Forrest JK,Deeb GM,Yakubov SJ,et al. 3-year outcomes after transcatheter or surgical aortic valve replacement in low-risk patients with aortic stenosis[J]. J Am Coll Cardiol ,2023,81(17):1663-1674.
[7] Mack MJ,Leon MB,Thourani VH,et al. Transcatheter aortic-valve replacement in low-risk patients at five years[J]. N Engl J Med ,2023,389(21):1949-1960.
[8] Thyregod HGH,J?rgensen TH,Ihlemann N,et al. Transcatheter or surgical aortic valve implantation:10-year outcomes of the NOTION trial[J]. Eur Heart J ,2024,45(13):1116-1124.
[9] Galper BZ,Chinnakondepalli KM,Wang K,et al. Economic outcomes of transcatheter versus surgical aortic valve replacement in patients with severe aortic stenosis and low surgical risk:results from the PARTNER 3 trial[J]. Circulation ,2023,147(21):1594-1605.
[10] UK TAVI Trial Investigators,Toff WD,Hildick-Smith D,et al. Effect of transcatheter aortic valve implantation vs surgical aortic valve replacement on all-cause mortality in patients with aortic stenosis:a randomized clinical trial[J]. JAMA ,2022,327(19):1875-1887.
[11] Annabi MS,C?té N,Dahou A,et al. Comparison of early surgical or transcatheter aortic valve replacement versus conservative management in low-flow,low-gradient aortic stenosis using inverse probability of treatment weighting:results from the TOPAS prospective observational cohort study[J]. J Am Heart Assoc ,2020,9(24):e017870.
[12] Ueyama H,Kuno T,Harrington M,et al. Impact of surgical and transcatheter aortic valve replacement in low-gradient aortic stenosis:a meta-analysis[J]. JACC Cardiovasc Interv ,2021,14(13):1481-1492.
[13] Kang DH,Park SJ,Lee SA,et al. Early surgery or conservative care for asymptomatic aortic stenosis[J]. N Engl J Med ,2020,382(2):111-119.
[14] Banovic M,Putnik S,Penicka M,et al. Aortic valve replacement versus conservative treatment in asymptomatic severe aortic stenosis:the AVATAR trial[J]. Circulation ,2022,145(9):648-658.
[15] Javadikasgari H,McGurk S,Newell PC,et al. Evolving concept of aortic valve replacement in asymptomatic patients with severe aortic stenosis[J]. Ann Thorac Surg ,2024,117(4):796-803.
[16] El-Hamamsy I,Toyoda N,Itagaki S,et al. Propensity-matched comparison of the Ross procedure and prosthetic aortic valve replacement in adult s[J]. J Am Coll Cardiol ,2022,79(8):805-815.
[17] Mazine A,David TE,Stoklosa K,et al. Improved outcomes following the Ross procedure compared with bioprosthetic aortic valve replacement[J]. J Am Coll Cardiol ,2022,79(10):993-1005.
[18] Sá MP,van den Eynde J,Jacquemyn X,et al. Long-term outcomes of Ross procedure versus mechanical aortic valve replacement:meta-analysis of reconstructed time-to-event data[J]. Trends Cardiovasc Med ,2024,34(1):29-36.
[19] Mylonas KS,Tasoudis PT,Pavlopoulos D,et al. Aortic valve neocuspidization using the Ozaki technique:a meta-analysis of reconstructed patient-level data[J]. Am Heart J ,2023,255:1-11.
[20] Unai S,Ozaki S,Johnston DR,et al. Aortic valve reconstruction with autologous pericardium versus a bioprosthesis:the Ozaki procedure in perspective[J]. J Am Heart Assoc ,2023,12(2):e027391.
[21] Toutouzas K,Benetos G,Voudris V,et al. Pre-dilatation versus no pre-dilatation for implantation of a self-expanding valve in all comers undergoing TAVR:the DIRECT trial[J]. JACC Cardiovasc Interv ,2019,12(8):767-777.
[22] Bandyopadhyay D,Chakraborty S,Amgai B,et al. Urgent balloon aortic valvuloplasty or urgent TAVR in patients with severe aortic stenosis:a propensity-matched analysis[J]. JACC Cardiovasc Interv ,2020,13(2):274-275.
[23] Ali N,Patel P,Wahab A,et al. A cohort study examining urgent and emergency treatment for decompensated severe aortic stenosis[J]. J Cardiovasc Med (Hagerstown) ,2021,22(2):126-132.
[24] Messas E,IJsselmuiden A,Goudot G,et al. Feasibility and performance of noninvasive ultrasound therapy in patients with severe symptomatic aortic valve stenosis:a first-in-human study[J]. Circulation ,2021,143(9):968-970.
[25] Trifunovic-Zamaklar D,Velinovi? M,Kova?evi?-Kosti? N,et al. Systematic brain magnetic resonance imaging and safety evaluation of non-invasive ultrasound therapy for patients with severe symptomatic aortic valve stenosis[J]. Eur Heart J Cardiovasc Imaging ,2023,24(7):e108-e109.
[26] Messas E,Ijsselmuiden A,Trifunovi?-Zamaklar D,et al. Treatment of severe symptomatic aortic valve stenosis using non-invasive ultrasound therapy:a cohort study[J]. Lancet ,2023,402(10419):2317-2325.
[27] Nicholls SJ,Nissen SE,Fleming C,et al. Muvalaplin,an oral small molecule inhibitor of lipoprotein(a) formation:a randomized clinical trial[J]. JAMA ,2023,330(11):1042-1053.
[28] Nissen SE,Linnebjerg H,Shen X,et al. Lepodisiran,an extended-duration short interfering RNA targeting lipoprotein(a):a randomized dose-ascending clinical trial[J]. JAMA ,2023,330(21):2075-2083.
[29] Bergmark BA,O’Donoghue ML,Murphy SA,et al. An exploratory analysis of proprotein convertase subtilisin/kexin type 9 inhibition and aortic stenosis in the FOURIER trial [J]. JAMA Cardiol ,2020,5(6):709-713.
[30] Zhang B,Roos C,Hagler M,et al. Activation of oxidized soluble guanylate cyclase slows progression of aortic valve calcification[J]. Arterioscler Thromb Vasc Biol,2019,39(suppl 1):A123.
[31] Lee S,Lee SA,Choi B,et al. Dipeptidyl peptidase-4 inhibition to prevent progression of calcific aortic stenosis[J]. Heart ,2020,106(23):1824-1831.
[32] Raggi P,Bellasi A,Bushinsky D,et al. Slowing progression of cardiovascular calcification with SNF472 in patients on hemodialysis:results of a randomized phase 2b study[J]. Circulation ,2020,141(9):728-739.
[33] Pawade TA,Doris MK,Bing R,et al. Effect of denosumab or alendronic acid on the progression of aortic stenosis:a double-blind randomized controlled trial[J]. Circulation ,2021,143(25):2418-2427.
[34] Ramchand J,Patel SK,Kearney LG,et al. Plasma ACE2 activity predicts mortality in aortic stenosis and is associated with severe myocardial fibrosis[J]. JACC Cardiovasc Imaging ,2020,13(3):655-664.
[35] Chen S,Redfors B,Nazif T,et al. Impact of renin-angiotensin system inhibitors on clinical outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement:an analysis of from the PARTNER 2 trial and registries[J]. Eur Heart J ,2020,41(8):943-954.
[36] Brandenburg VM,Reinartz S,Kaesler N,et al. Slower progress of aortic valve calcification with vitamin K supplementation :results from a prospective interventional proof-of-concept study[J]. Circulation ,2017,135(21):2081-2083.
[37] Diederichsen ACP,Lindholt JS,M?ller S,et al. Vitamin K2 and D in patients with aortic valve calcification:a randomized double-blinded clinical trial[J]. Circulation ,2022,145(18):1387-1397.
[38] En Q,Zeping H,Yuetang W,et al. Metformin alleviates the calcification of aortic valve interstitial cells through activating the PI3K/AKT pathway in an AMPK dependent way[J]. Mol Med ,2021,27(1):156.
[39] Matilla L,Martín-Nú?ez E,Garaikoetxea M,et al. Sex-specific role of galectin-3 in aortic stenosis[J]. Biol Sex Differ ,2023,14(1):72.
[40] Rogers MA,Bartoli-Leonard F,Zheng KH,et al. Major facilitator superfamily domain containing 5 inhibition reduces lipoprotein(a) uptake and calcification in valvular heart disease[J]. Circulation ,2024,149(5):391-401.
[41] Thériault S,Li Z,Abner E,et al. Integrative genomic analyses identify candidate causal genes for calcific aortic valve stenosis involving tissue-specific regulation[J]. Nat Commun ,2024,15(1):2407.
相似文献/References:
[1]于海波,综述,梁延春,等.经导管主动脉瓣膜置换术后房室传导阻滞的预警[J].心血管病学进展,2016,(4):419.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.024]
YU Haibo,LIANG Yanchun.Predicting Factors of Atrioventricular Block after Transcatheter
Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2016,(11):419.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.024]
[2]谢晓川,饶莉.经导管主动脉瓣植入术临床研究进展[J].心血管病学进展,2015,(6):700.[doi:10.3969/j.issn.1004-3934.2015.06.011]
XIE Xiaochuan,RAO Li.Clinical Research Progress in Transcatheter Aortic Valve Implantation[J].Advances in Cardiovascular Diseases,2015,(11):700.[doi:10.3969/j.issn.1004-3934.2015.06.011]
[3]于子凯 许海燕 刘庆荣 吴永健.合并常见疾病对经导管主动脉瓣置换术患者预后的影响[J].心血管病学进展,2019,(5):697.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.009]
YU Zikai,XU Haiyan,LIU Qingrong,et al.Influence of ommon Accompanied Diseases on Prognosis of Patients after Transcatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2019,(11):697.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.009]
[4]邵美华 周玉强 王萌萌 王宝珠 马翔.经导管主动脉瓣置换术治疗二叶式主动脉瓣狭窄研究进展[J].心血管病学进展,2020,(11):1184.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
[5]夏平.“8+2”心电图临床价值的研究进展夏平[J].心血管病学进展,2021,(9):800.[doi:【DOI】10.16806/j.cnki.issn.1004-3934.2021.09.009]
XIA Ping.Clinical Value of 8 Plus 2 ECG[J].Advances in Cardiovascular Diseases,2021,(11):800.[doi:【DOI】10.16806/j.cnki.issn.1004-3934.2021.09.009]
[6]李宗泽 何贵均 郑晓菲 蒋晖 刘汉雄.经导管主动脉瓣置换术后合并心房颤动的抗栓策略[J].心血管病学进展,2021,(10):892.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.007]
LI ZongzeHE GuijunZHENG XiaofeiJIANG HuiLIU Hanxiong.Optimal Antithrombotic Strategies after Transcatheter Aortic Valve Replacement in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(11):892.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.007]
[7]王卫卫 于子凯 吴永健 许海燕 刘庆荣.序贯综合心脏康复模式在经导管主动脉瓣置换术患者中应用现状[J].心血管病学进展,2022,(8):673.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.001]
WANG Weiwei,YU Zikai,WU YongjianXU HaiyanLIU Qingrong.The Status of Sequential Comprehensive Cardiac Rehabilitation in Patients?ndergoing Transcatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2022,(11):673.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.001]
[8]张航 安景辉 石凤梧.极简式经导管主动脉瓣置换术的研究现状[J].心血管病学进展,2022,(9):812.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.011]
ZHANG Hang,AN Jinghui,SHI Fengwu.Minimalist Transcatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2022,(11):812.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.011]
[9]达尼亚尔·迪力木拉提 施林 严飞.二叶式主动脉瓣发病机制及其临床诊治的研究进展[J].心血管病学进展,2023,(5):412.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.007]
Daniyar·Dilmurat,SHI Lin,YAN Fei.The PathogenesisClinical Diagnosis and Treatment of Bicuspid Aortic Valve[J].Advances in Cardiovascular Diseases,2023,(11):412.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.007]
[10]吴文军 谢玲 李婷婷 丁任重 胡义杰.经导管主动脉瓣置换术围手术期脑卒中和脑保护研究进展[J].心血管病学进展,2024,(4):295.[doi:10.16806/j.cnki.issn.1004-3934.2024.04.002]
WU Wenjun,XIE Ling,LI Tingting,et al.Perioperative Transcatheter Aortic Valve Replacement for Stroke and Cerebral Protection[J].Advances in Cardiovascular Diseases,2024,(11):295.[doi:10.16806/j.cnki.issn.1004-3934.2024.04.002]